Effectiveness and Risk Factors for Virological Outcome of Raltegravir-Based Therapy for Treatment-Experienced HIV-Infected Patients. - Wikidata - wikimedia - TriplyDB

Effectiveness and Risk Factors for Virological Outcome of Raltegravir-Based Therapy for Treatment-Experienced HIV-Infected Patients.

Effectiveness and Risk Factors for Virological Outcome of Raltegravir-Based Therapy for Treatment-Experienced HIV-Infected Patients.

http://www.wikidata.org/entity/Q37653463

about

Effectiveness and Risk Factors for Virological Outcome of Raltegravir-Based Therapy for Treatment-Experienced HIV-Infected Patients.

http://www.wikidata.org/entity/Q37653463

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 25 January 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Effectiveness and Risk Factors ...... rienced HIV-Infected Patients.

@en

Effectiveness and Risk Factors ...... rienced HIV-Infected Patients.

@nl

type

label

Effectiveness and Risk Factors ...... rienced HIV-Infected Patients.

@en

Effectiveness and Risk Factors ...... rienced HIV-Infected Patients.

@nl

prefLabel

Effectiveness and Risk Factors ...... rienced HIV-Infected Patients.

@en

Effectiveness and Risk Factors ...... rienced HIV-Infected Patients.

@nl

P1433

Q37653463-103F0FBB-BC92-4A33-9F61-FFC3C185092C

P1476

Q37653463-3B5605E3-8C78-4DD7-9CBC-88F3390F61AB

P2093

Q37653463-1A20ED9D-50A3-4CE4-B960-716DC1ED4866

Q37653463-1AEEEF19-F0F4-4290-A861-221AD05EB7C7

Q37653463-36D15A9C-023F-4007-8552-846A86827AFA

Q37653463-3D11D58D-936C-4023-9B0C-2618E5EAF215

Q37653463-502D9C49-C605-4F2D-A8E5-6E1BFE109DFE

Q37653463-7BFFC180-6895-4EBC-A261-D19C414D29D2

Q37653463-A4BC965B-3F69-43B6-9E90-8D7DB1BF8BE8

Q37653463-A4C906E1-4E5D-4ACA-BEC8-6C0C4CF53C4E

Q37653463-D73EE9B2-7925-4583-BEB8-7897A21DAE49

Q37653463-E92A36C2-C757-4EA7-82C3-6425C03BF03D

P2860

Q37653463-20634C62-8307-4A39-9B59-4A1F2E66ACDB

Q37653463-3B689603-497E-48C5-BBCA-9CF5229A5460

Q37653463-4270DAAC-F986-4EA3-A9F6-9FDDAB8B7CA7

Q37653463-4456F180-6BBB-4AB3-84B7-A6866293B0BA

Q37653463-4F8A7EAB-B6F3-436C-9931-B907BC2C835F

Q37653463-56C97D0B-D9DE-492C-B578-C35213D2A614

Q37653463-5C1CE0A9-522C-4C2A-B001-01F20A547D1E

Q37653463-A11D3734-4E8A-46E9-8BCB-9236F2B01200

Q37653463-A43CE744-D562-43E6-A7B4-30189D5B1E57

Q37653463-D16A4373-1856-4044-B882-7CED8DB1A9F7

P304

Q37653463-2EDC0879-4E3E-4AA5-A31C-20CD626EEC9F

P31

Q37653463-3C23BD98-A390-4B21-97CE-4946A00DF7C5

P356

Q37653463-2E401907-598A-420C-B1B8-4A1A86C401EA

P433

Q37653463-AD88B8E0-066C-4A22-8896-870BDDD8D529

P478

Q37653463-58F848E4-9455-4A96-A211-A2E3C929B13C

P50

Q37653463-911886D2-D79E-48C2-A7A1-8368A278D22C

P577

Q37653463-CC424789-014A-4760-AF4B-4A1CB1A35AB0

P698

Q37653463-289C60E0-74FE-4E6B-813E-FFB09CC8DF23

P921

Q37653463-88B677DC-19FF-4899-940D-1EA0F4982DD1

P932

Q37653463-7C462B52-104F-456D-992B-6B5EDA170639

P356

S40268-017-0174-Z

P1433

P1476

Effectiveness and Risk Factors ...... erienced HIV-Infected Patients

@en

P2093

Alberto Chaparro Sánchez

http://www.w3.org/2001/XMLSchema#string

Alma Minerva Pérez Rios

http://www.w3.org/2001/XMLSchema#string

Ariane Estrella Weiser Smeke

http://www.w3.org/2001/XMLSchema#string

Irene Juarez-Kasusky

http://www.w3.org/2001/XMLSchema#string

Javier Enrique Cruz Herrera

http://www.w3.org/2001/XMLSchema#string

Jesús Gaytán-Martínez

http://www.w3.org/2001/XMLSchema#string

Jorge Luis Sandoval Ramírez

http://www.w3.org/2001/XMLSchema#string

Juan Carlos Domínguez-Hermosillo

http://www.w3.org/2001/XMLSchema#string

Marcelino Chávez-García

http://www.w3.org/2001/XMLSchema#string

Marco Isaac Banda-Lara

http://www.w3.org/2001/XMLSchema#string

P2860

Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E Study.

Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial.

Raltegravir: the first HIV integrase inhibitor.

Association between first-year virological response to raltegravir and long-term outcomes in treatment-experienced patients with HIV-1 infection.

Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK Study.

Effectiveness and risk factors for virological outcome of darunavir-based therapy for treatment-experienced HIV-infected patients

Clinical and Virologic Outcomes After Changes in First Antiretroviral Regimen at 7 Sites in the Caribbean, Central and South America Network

Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor.

Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group.

Virological failure to raltegravir in Spain: incidence, prevalence and clinical consequences.

P304

225-231

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40268-017-0174-Z

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

José Antonio Mata-Marín

P577

2017-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28124232

http://www.w3.org/2001/XMLSchema#string

P921

P932

5318342

http://www.w3.org/2001/XMLSchema#string